Laboratory correlation between vancomycin levels and serum creatinine in the nephrotoxicity of vancomycin

References

• Cano, E. L., Haque, N. Z., Welch, V. L., Cely, C. M., Peyrani, P., Scerpella, E. G., ... Kett, D. H. (2012). Incidence of nephrotoxicity and association with vancomycin use in intensive care unit patients with pneumonia: Retrospective analysis of the IMPACT-HAP database. Clinical Therapeutics, 34, 149–157.10.1016/j.clinthera.2011.12.013
   Google Scholar
• Carreno, J. J., Kenney, R. M., & Lomaestro, B. (2014). Vancomycin-associated renal dysfunction: Where are we now? Pharmacotherapy, 34, 1259–1268.
   Google Scholar
• Cosgrove, S. E., Vigliani, G. A., Campion, M., Fowler, Jr., V. G., Abrutyn, E., Corey, G. R., ... Boucher, H. W. (2009). Initial low‐dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. Clinical Infectious Diseases, 48, 713–721.10.1086/598174
   Google Scholar
• Davis, S. L., Scheetz, M. H., Bosso, J. A., Goff, D. A., & Rybak, M. J. (2013). Adherence to the 2009 consensus guidelines for vancomycin dosing and monitoring practices: A cross-sectional survey of U.S. hospitals. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 33, 1256–1263.10.1002/phar.1327
   Google Scholar
• Gupta, A., Biyani, M., & Khaira, A. (2011). Vancomycin nephrotoxicity: Myths and facts. Netherlands Journal of Medicine, 69, 379–383.
   Google Scholar
• Hal, S. J. V., Paterson, D. L., & Lodise, T. P. (2013). Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob Agents Chemother, 57, 734–744.
   Google Scholar
• Hall, 2nd., R. G., Hazlewood, K. A., Brouse, S. D., Giuliano, C. A., Haase, K. K.Frei, C. R., ... Alvarez, C. A. (2013). Empiric guideline-recommended weight-based vancomycin dosing and nephrotoxicity rates in patients with methicillin-resistant Staphylococcus aureus bacteremia: A retrospective cohort study. BMC Pharmacology and Toxicology, 14, 2138.10.1186/2050-6511-14-12
   Google Scholar
• Hidayat, L. K., Hsu, D. I., Quist, R., Shriner, K. A., & Wong-Beringer, A. (2006). High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections. Archives of Internal Medicine, 166, 2138–2144.10.1001/archinte.166.19.2138
   Google Scholar
• Horey, A., Mergenhagen, K. A., & Mattappallil, A. (2012). The relationship of nephrotoxicity to vancomycin trough serum concentrations in a veteran’s population: A retrospective analysis. Annals of Pharmacotherapy, 46, 1477–1483.10.1345/aph.1R158
   Google Scholar
• Jeffres, M. N., Isakow, W., Doherty, J. A., Micek, S. T., & Kollef, M. H. (2007). A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin- resistant Staphylococcus aureus pneumonia. Clinical Therapeutics, 29, 1107–1115.10.1016/j.clinthera.2007.06.014
   Google Scholar
• Kullar, R., Davis, S. L., Taylor, T. N., Kaye, K. S., & Rybak, M. J. (2012). Effects of targeting higher vancomycin trough levels on clinical outcomes and costs in a matched patient cohort. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 32, 195–201.10.1002/phar.2012.32.issue-3
   Google Scholar
• Levine, D. P. (2006). Vancomycin: A history. Clinical Infectious Diseases, 42, S5–S12.10.1086/491709
   Google Scholar
• Lodise, T. P., Lomaestro, B., Graves, J., & Drusano, G. L. (2008). Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrobial Agents and Chemotherapy, 52, 1330–1336.10.1128/AAC.01602-07
   Google Scholar
• Lodise, T. P., Patel, N., Lomaestro, B. M., Rodvold, K. A., & Drusano, G. L. (2009). Relationship between initial vancomycin concentration‐time profile and nephrotoxicity among hospitalized patients. Clinical Infectious Diseases, 49, 507–514.10.1086/599188
   Google Scholar
• Marinho, D. S., Huf, G., Ferreira, B. L. A., Castro, H., Rodrigues, C. R., Sousa, V. P., & Cabral, L. M. (2011). The study of vancomycin use and its adverse reactions associated to patients of a Brazilian university hospital. BMC Research Notes, 4, 236.10.1186/1756-0500-4-236
   Google Scholar
• Minejima, E., Choi, J., Beringer, P., Lou, M., Tse, E., & Wong-Beringer, A. (2011). Applying new diagnostic criteria for acute kidney injury to facilitate early identification of nephrotoxicity in vancomycin-treated patients. Antimicrobial Agents and Chemotherapy, 55, 3278–3283.10.1128/AAC.00173-11
   Google Scholar
• Pea, F., Furlanut, M., Negri, C., Pavan, F., Crapis, M., Cristini, F., & Viale, P. (2009). Prospectively validated dosing nomograms for maximizing the pharmacodynamics of vancomycin administered by continuous infusion in critically ill patients. Antimicrobial Agents and Chemotherapy, 53, 1863–1867.10.1128/AAC.01149-08
   Google Scholar
• Perazella, M. A. (2009). Renal vulnerability to drug toxicity. Clinical Journal of the American Society of Nephrology, 4, 1275–1283.10.2215/CJN.02050309
   Google Scholar
• Pritchard, L., Baker, C., Leggett, J., Sehdev, P., Brown, A., & Bayley, K. B. (2010). Increasing vancomycin serum trough concentrations and incidence of nephrotoxicity. The American Journal of Medicine, 123, 1143–1149.10.1016/j.amjmed.2010.07.025
   Google Scholar
• Roberts, J. A., Abdul-Aziz, M. H., Lipman, J., Mouton, J. W., Vinks, A. A., Felton, T. W., ... Kuti, J. L. (2014). Individualised antibiotic dosing for patients who are critically ill: Challenges and potential solutions. The Lancet Infectious Diseases, 14, 498–509.10.1016/S1473-3099(14)70036-2
   Google Scholar
• Rybak, M. J., Albrecht, L. M., Boike, S. C., & Chandrasekar, P. H. (1990). Nephrotoxicity of vancomycin, alone and with an aminoglycoside. Journal of Antimicrobial Chemotherapy, 25, 679–687.10.1093/jac/25.4.679
   Google Scholar
• Rybak, M. J., Lomaestro, B. M., Rotschafer, J. C., Moellering, Jr., R., Craig, W. A., Billeter, M., ... Levine, D. P. (2009a). Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. American Journal of Health-System Pharmacy, 66, 82–98.10.2146/ajhp080434
   Google Scholar
• Rybak, M. J., Lomaestro, B. M., Rotschafer, J. C., Moellering, Jr., R. C., Craig, W. A., Billeter, M., ... Levine, D. P. (2009b Aug). Vancomycin therapeutic guidelines: A summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clinical Infectious Diseases, 49, 325–327.10.1086/599187
   Google Scholar
• Satoskar, A. A., Nadasdy, G., Plaza, J. A., Sedmak, D., Shidham, G., Hebert, L., & Nadasdy, T. (2006). Staphylococcus infection-associated glomerulonephritis mimicking IgA nephropathy. Clinical Journal of the American Society of Nephrology, 1, 1179–1186.10.2215/CJN.01030306
   Google Scholar
• Tattevin, P., Saleh-Mghir, A., Davido, B., Ghout, I., Massias, L., Garcia de la Maria, C., ... Cremieux, A. C. (2013). Comparison of six generic vancomycin products for treatment of methicillin-resistant Staphylococcus aureus experimental endocarditis in rabbits. Antimicrobial Agents and Chemotherapy, 57, 1157–1162.10.1128/AAC.01669-12
   Google Scholar
• Tattevin, P., Cremieux, A. C., Rabaud, C., & Gauzit, R. (2014). Efficacy and quality of antibacterial generic products approved for human use: A systematic review. Clinical Infectious Diseases, 58, 458–469.10.1093/cid/cit769
   Google Scholar
• Vandecasteele, S. J., & De Vriese, A. S. (2010). Recent changes in vancomycin use in renal failure. Kidney International, 77, 760–764.10.1038/ki.2010.35
   Google Scholar
• Vandecasteele, S. J., & De Vriese, A. S. (2011). Vancomycin dosing in patients on intermittent hemodialysis. Seminars in Dialysis, 24, 50–55.10.1111/sdi.2011.24.issue-1
   Google Scholar
• van Hal, S. J., & Fowler, Jr., V. G. (2013). Is it time to replace vancomycin in the treatment of methicillin-resistant Staphylococcus aureus infections? Clinical Infectious Diseases, 56, 1779–1788.10.1093/cid/cit178
   Google Scholar